126 related articles for article (PubMed ID: 10636481)
1. Superantigen presenting capacity of human astrocytes.
Hassan-Zahraee M; Ladiwala U; Lavoie PM; McCrea E; Sekaly RP; Owens T; Antel JP
J Neuroimmunol; 2000 Jan; 102(2):131-6. PubMed ID: 10636481
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.
Bavari S; Ulrich RG
Infect Immun; 1995 Feb; 63(2):423-9. PubMed ID: 7822006
[TBL] [Abstract][Full Text] [Related]
4. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Brogan PA; Shah V; Klein N; Dillon MJ
Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
[TBL] [Abstract][Full Text] [Related]
5. Human natural killer (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes.
D'Orazio JA; Stein-Streilein J
Clin Exp Immunol; 1996 May; 104(2):366-73. PubMed ID: 8625534
[TBL] [Abstract][Full Text] [Related]
6. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.
Thibodeau J; Cloutier I; Lavoie PM; Labrecque N; Mourad W; Jardetzky T; Sékaly RP
Science; 1994 Dec; 266(5192):1874-8. PubMed ID: 7997881
[TBL] [Abstract][Full Text] [Related]
7. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
[TBL] [Abstract][Full Text] [Related]
8. Transcytosis of staphylococcal superantigen toxins.
Hamad AR; Marrack P; Kappler JW
J Exp Med; 1997 Apr; 185(8):1447-54. PubMed ID: 9126925
[TBL] [Abstract][Full Text] [Related]
9. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
Lamphear JG; Stevens KR; Rich RR
J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcal toxins bind to different sites on HLA-DR.
Chintagumpala MM; Mollick JA; Rich RR
J Immunol; 1991 Dec; 147(11):3876-81. PubMed ID: 1940373
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules.
Scholl PR; Diez A; Geha RS
J Immunol; 1989 Oct; 143(8):2583-8. PubMed ID: 2551962
[TBL] [Abstract][Full Text] [Related]
12. Receptors for toxic shock syndrome toxin-1 and staphylococcal enterotoxin A on human blood monocytes.
See RH; Krystal G; Chow AW
Can J Microbiol; 1992 Sep; 38(9):937-44. PubMed ID: 1281444
[TBL] [Abstract][Full Text] [Related]
13. Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators.
Pless DD; Ruthel G; Reinke EK; Ulrich RG; Bavari S
Infect Immun; 2005 Sep; 73(9):5358-66. PubMed ID: 16113251
[TBL] [Abstract][Full Text] [Related]
14. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation.
Poncet P; Arock M; David B
J Leukoc Biol; 1999 Jul; 66(1):105-12. PubMed ID: 10410997
[TBL] [Abstract][Full Text] [Related]
15. Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1.
Shimonkevitz R; Boen E; Malmstrom S; Brown E; Hurley JM; Kotzin BL; Matsumura M
Infect Immun; 1996 Apr; 64(4):1133-9. PubMed ID: 8606069
[TBL] [Abstract][Full Text] [Related]
16. A novel HLA class II-independent TCR-mediated T cell activation mechanism is distinguished by the V beta specificity of the proliferating oligoclones and their capacity to generate interleukin-2.
Dennig D; Yan Y; Ferguson K; O'Reilly RJ
Cell Immunol; 1996 Aug; 171(2):200-10. PubMed ID: 8806788
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the interaction of superantigen with the alternative superantigen-binding receptor p85.
Rogers TJ; Zhang L
Mol Immunol; 1997 Feb; 34(3):263-72. PubMed ID: 9224968
[TBL] [Abstract][Full Text] [Related]
18. Activation of human T cells by toxic shock syndrome toxin-1: the toxin-binding structures expressed on human lymphoid cells acting as accessory cells are HLA class II molecules.
Uchiyama T; Imanishi K; Saito S; Araake M; Yan XJ; Fujikawa H; Igarashi H; Kato H; Obata F; Kashiwagi N
Eur J Immunol; 1989 Oct; 19(10):1803-9. PubMed ID: 2583222
[TBL] [Abstract][Full Text] [Related]
19. Production of tumour necrosis factors by human T cells stimulated by a superantigen, toxic shock syndrome toxin-1.
Akatsuka H; Imanishi K; Inada K; Yamashita H; Yoshida M; Uchiyama T
Clin Exp Immunol; 1994 Jun; 96(3):422-6. PubMed ID: 7911750
[TBL] [Abstract][Full Text] [Related]
20. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
